Abstract

Several phosphorus-substituted N-acylated cyanoaziridines 2 and N-carbamoylated cyanoziridines 5 were prepared in good to high yields. N-Acylated cyanoaziridines 2 were used, after ring expansion, in an efficient synthesis of oxazoline derivative 3a and in a completely regio-controlled reaction in the presence of NaI. Conversely, N-carbamoyl cyanoaziridines 5 reacted with NaI to obtain a regioisomeric mixture of 2-aminocyanooxazolines 7. Mild acidic conditions can be used for the isomerization of N-thiocarbamoyl cyanoaziridine 6a into a 2-aminocyanothiazoline derivative 8a by using BF3·OEt2 as a Lewis acid. Likewise, a one pot reaction of NH-cyanoaziridines 1 with isocyanates obtained 2-iminocyanooxazolidines 9 regioselectively. This synthetic methodology involves the addition of isocyanates to starting cyanoaziridines to obtain N-carbamoyl cyanoaziridines 5, which after the ring opening, reacts with a second equivalent of isocyanate to give the final 2-imino cyanooxazolidines 9. In addition, the cytotoxic effect on the cell lines derived from human lung adenocarcinoma (A549) was also screened. 2-Iminooxazolidines 9 exhibited moderate activity against the A549 cell line in vitro. Furthermore, a selectivity towards cancer cells (A549) over non-malignant cells (MCR-5) was detected.

Highlights

  • DNA-modifying agents are a significant class of pharmaceuticals used in conventional chemotherapy

  • In a sealed-tube, 4-cyanooxazoline derived from phosphine oxide 3a was obtained in a regioselective way in a 65% yield (Scheme 2)

  • The best result was observed for N-acylated cyanoaziridine 2a derived from phosphine oxide with an IC50 value of 22.9 ± 1.9 μM (Table 5, entry 2)

Read more

Summary

Introduction

DNA-modifying agents are a significant class of pharmaceuticals used in conventional chemotherapy. Aziridine-based cytostatic compounds, acting as powerful alkylating agents, have an inherent in vivo potency due to their ability to act as DNA cross-linking agents via the ring opening of aziridine [1]. Mitomycin C is a conventional DNA cross-linking agent that uses the reductive activation of the aziridine moiety to form lethal DNA–DNA cross-links, as well as, more often, mono-alkylated DNA products [3]. Founded on this knowledge, during the early 1970s Bicker [4,5] developed a variety of 2-cyanoaziridine derivatives as potential carcinostatic agents.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call